Pfizer 2012 Annual Report Download - page 55

Download and view the complete annual report

Please find page 55 of the 2012 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 121

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121

Consolidated Statements of Comprehensive Income
Pfizer Inc. and Subsidiary Companies
54
2012 Financial Report
Year Ended December 31,
(MILLIONS OF DOLLARS) 2012 2011 2010
Net income before allocation to noncontrolling interests $14,598 $10,049 $8,288
Foreign currency translation adjustments $(811)$796 $(3,534)
Reclassification adjustments(a) (207)(127)(7)
(1,018) 669 (3,541)
Unrealized holding gains/(losses) on derivative financial instruments 684 (502)(1,043)
Reclassification adjustments for realized (gains)/losses(b) (263)239 702
421 (263)(341)
Unrealized holding gains/(losses) on available-for-sale securities 135 (143)7
Reclassification adjustments for realized (gains)/losses(b) 315 (141)
138 (128)(134)
Benefit plans: Actuarial losses, net (2,232) (2,459)(1,426)
Reclassification adjustments related to amortization(c) 473 284 262
Reclassification adjustments related to curtailments and settlements, net(c) 317 355 266
Other 22 (100)88
(1,420) (1,920)(810)
Benefit plans: Prior service credits and other 25 106 550
Reclassification adjustments related to amortization(c) (69)(69)(42)
Reclassification adjustments related to curtailments and settlements, net(c) (130)(91)(49)
Other (3) 35
(177)(51)464
Other comprehensive loss, before tax (2,056) (1,693)(4,362)
Tax benefit on other comprehensive loss(d) (225)(959)(375)
Other comprehensive loss before allocation to noncontrolling interests $(1,831)$(734)$ (3,987)
Comprehensive income before allocation to noncontrolling interests $12,767 $9,315 $4,301
Less: Comprehensive income/(loss) attributable to noncontrolling interests 21 (5) 36
Comprehensive income attributable to Pfizer Inc. $12,746 $9,320 $4,265
(a) For 2012 and 2011, reclassified to Gain/(loss) on sale of discontinued operations—net of tax.
(b) Reclassified into Other deductions—net in the consolidated statements of income.
(c) Generally reclassified into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in
the consolidated statements of income.
(d) See Note 5E. Tax Matters: Taxes on Items of Other Comprehensive Income/(Loss).
See Notes to Consolidated Financial Statements, which are an integral part of these statements.